(Q43545011)

24 November 2017

title

Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors (English)

1 reference

24 November 2017

1

Guy Boivin

1 reference

24 November 2017

Nathalie Goyette

2

1 reference

24 November 2017

publication date

1 June 2002

1 reference

24 November 2017

1 reference

24 November 2017

volume

54

1 reference

24 November 2017

issue

3

1 reference

24 November 2017

page(s)

143-147

1 reference

Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir

24 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900219-4

7 January 2021

Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900219-4

7 January 2021

Rapid antiviral effect of inhaled zanamivir in the treatment of naturally occurring influenza in otherwise healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900219-4

7 January 2021

Evaluation of a rapid optical immunoassay for influenza viruses (FLU OIA test) in comparison with cell culture and reverse transcription-PCR

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900219-4

7 January 2021

Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900219-4

7 January 2021

Prevention and treatment of influenza

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900219-4

7 January 2021

Influenza virus neuraminidase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900219-4

7 January 2021

Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900219-4

7 January 2021

Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900219-4

7 January 2021

Resistance of influenza viruses to neuraminidase inhibitors--a review.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900219-4

7 January 2021

In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900219-4

7 January 2021

Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900219-4

7 January 2021

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900219-4

7 January 2021

10.1016/S0166-3542(01)00219-4

Identifiers

DOI

1 reference

24 November 2017

1 reference